January 26, 2012Open Access

Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the rate of pathological complete response, which was the primary end point of this study. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00408408.).

Bookmark

View Full Paper

Cite This Study

Bear et al. (Thu,) studied this question.

synapsesocial.com/papers/69de98ee5e582bd3c5e93bfa https://doi.org/https://doi.org/10.1056/nejmoa1111097

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Abstract S4-1: FinXX Final 5-Year Analysis: Results of the Randomised, Open-Label, Phase III Trial in Medium-to-High Risk Early Breast Cancer2010 · 14 citations
2Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer2010 · 39 citations
3Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.1997 · 1,809 citations
4New Guidelines to Evaluate the Response to Treatment in Solid Tumors2000 · 15,720 citations
5tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC)2008 · 46 citations

Bookmark

View Full Paper